- Home
- SEER vs SGMO Comparison
SEER vs SGMO Comparison
Compare SEER & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- SGMO
- Stock Information
- Founded
- SEER 2017
- SGMO 1995
- Country
- SEER United States
- SGMO United States
- Employees
- SEER N/A
- SGMO N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEER Health Care
- SGMO Health Care
- Exchange
- SEER Nasdaq
- SGMO Nasdaq
- Market Cap
- SEER 113.8M
- SGMO 122.8M
- IPO Year
- SEER 2020
- SGMO 2000
- Fundamental
- Price
- SEER $2.15
- SGMO $0.55
- Analyst Decision
- SEER
- SGMO Strong Buy
- Analyst Count
- SEER 0
- SGMO 7
- Target Price
- SEER N/A
- SGMO $5.29
- AVG Volume (30 Days)
- SEER 139.2K
- SGMO 4.1M
- Earning Date
- SEER 11-05-2025
- SGMO 11-11-2025
- Dividend Yield
- SEER N/A
- SGMO N/A
- EPS Growth
- SEER N/A
- SGMO N/A
- EPS
- SEER N/A
- SGMO N/A
- Revenue
- SEER $16,288,000.00
- SGMO $81,706,000.00
- Revenue This Year
- SEER $27.77
- SGMO $21.24
- Revenue Next Year
- SEER $20.28
- SGMO N/A
- P/E Ratio
- SEER N/A
- SGMO N/A
- Revenue Growth
- SEER 10.52
- SGMO 565.52
- 52 Week Low
- SEER $1.62
- SGMO $0.41
- 52 Week High
- SEER $2.63
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- SEER 57.91
- SGMO 58.27
- Support Level
- SEER $2.03
- SGMO $0.49
- Resistance Level
- SEER $2.11
- SGMO $0.56
- Average True Range (ATR)
- SEER 0.06
- SGMO 0.04
- MACD
- SEER 0.01
- SGMO 0.00
- Stochastic Oscillator
- SEER 81.82
- SGMO 100.00
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.